Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)

NCT05076422 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05076422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
October 18, 2021
Completion date
March 3, 2023
Enrollment
80 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy